SAN FRANCISCOBack in November, news of a cardiovascular outcomes win for Trulicity pleased Eli Lilly investors whom analysts called skeptical. Now, those same skeptics may wonder just how well Trulicitys performance can help it fend off new competition from N…
Read More
ADA: Lilly’s Trulicity cuts heart risks by 12%. Is it enough to fend off Novo’s semaglutide? – FiercePharma
